Peptide Drug Conjugates Global Market Report 2025

The peptide drug conjugates market size has grown rapidly in recent years. It will grow from $3.16 billion in 2024 to $3.68 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth during the historic period can be attributed to several factors, including a favorable regulatory environment for biologics and peptides, an increase in orphan drug designations for peptide drugs, government incentives for rare disease treatments, the expanding biopharmaceutical sector, and rising global healthcare expenditure.

The peptide drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $6.6 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth during the forecast period can be attributed to factors such as the rising global prevalence of cancer, increasing demand for targeted cancer therapies, a growing pipeline of peptide-based drug candidates, the expansion of personalized medicine, and rising interest in combination therapies. Key trends expected to shape the forecast period include improvements in peptide synthesis techniques, advancements in linker technologies, enhanced site-specific conjugation methods, better tumor targeting capabilities, and innovations in payload selection.

The increasing demand for personalized treatments is expected to drive the growth of the peptide drug conjugates market in the coming years. Personalized treatments are therapies tailored to an individual’s unique genetic makeup, lifestyle, and disease characteristics to achieve the most effective outcomes. This rise is driven by advancements in genomics, which help identify specific disease markers, enabling more precise and effective therapies. In the case of peptide drug conjugates, personalized treatments allow for the selection of specific peptides that target unique disease biomarkers in patients, ensuring more precise and effective drug delivery. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA authorized 16 novel customized medicines for patients with rare disorders in 2023, a significant increase from the six authorized in 2022. As a result, the growing demand for personalized treatments is poised to accelerate the growth of the peptide drug conjugates market.

Leading companies in the peptide drug conjugates market are concentrating on developing advanced treatment options, such as tumor-selective peptide drug conjugates, to improve treatment precision. These therapies use peptides specifically engineered to bind to cancer cells, allowing for the direct delivery of cytotoxic agents to tumors while minimizing harm to healthy tissue. For example, in March 2025, Cybrexa Therapeutics, a US-based oncology biotechnology company, shared new preclinical data from its alphalex technology. The data highlighted the effectiveness of Cybrexa’s antigen-agnostic peptide-drug conjugate (PDC) platform in delivering powerful microtubule inhibitors directly to tumor cells. This approach not only suppresses tumor growth but also triggers a lasting anti-tumor immune response. The findings underscore the potential of Cybrexa’s technology in advancing cancer treatment.

In May 2023, Bayer AG, a Germany-based pharmaceutical company, entered into a strategic collaboration with Bicycle Therapeutics to develop novel radioconjugates targeting various oncology indications. Through this partnership, Bicycle Therapeutics will leverage its proprietary phage display platform to identify and optimize highly selective bicyclic peptides. Bayer will lead the preclinical and clinical development, as well as oversee manufacturing and commercialization efforts. The goal is to create targeted radiotherapy solutions that address critical gaps in cancer treatment. Bicycle Therapeutics is a UK-based company specializing in the development of peptide drug conjugates designed for precision oncology applications.

Major players in the peptide drug conjugates market are AstraZeneca PLC, Novartis AG, BioNTech SE, Curium US LLC, ADC Therapeutics SA, PeptiDream Incorporated, PepGen Corporation, Theratechnologies Inc., Italfarmaco Società per Azioni, Protagonist Therapeutics Inc., Alteogen Inc., Metsera Inc., Zealand Pharma A/S, Apellis Pharmaceuticals Inc., Angiochem Inc., Cybrexa Therapeutics Inc., Ambrx Inc., Oncopeptides Aktiebolag (AB), ProteinQure Incorporated, Soricimed Biopharma Inc., Esperance Pharmaceuticals Inc., Adcytherix SA, and Araris Biotech AG.

North America was the largest region in the peptide drug conjugates market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peptide drug conjugates report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Peptide drug conjugates (PDCs) are targeted treatments that combine peptides with cytotoxic drugs to enhance therapeutic precision. The peptide, which specifically binds to cell receptors, is conjugated with the drug, allowing it to target diseased cells, such as tumors, directly. This method improves the drug's stability, selectivity, and bioavailability, thereby boosting its therapeutic effectiveness while minimizing harm to healthy tissues.

The main types of peptide drug conjugates include therapeutic and diagnostic. A therapeutic peptide drug conjugate involves attaching a peptide to a drug, typically a cytotoxic agent, to target cancer cells or other diseased tissue directly. These PDCs are used in the treatment of oncology, immunology, infectious diseases, and more. They can be administered through various routes, including intravenous and subcutaneous, and are commonly used in hospitals, clinics, pharmacies, and other healthcare settings.

The peptide drug conjugate market research report is one of a series of new reports that provides peptide drug conjugate market statistics, including peptide drug conjugate industry global market size, regional shares, competitors with a peptide drug conjugate market share, detailed peptide drug conjugate market segments, market trends and opportunities, and any further data you may need to thrive in the peptide drug conjugate industry. This peptide drug conjugate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide drug conjugates market consists of revenues earned by entities by providing services such as conjugation services, preclinical testing, formulation development, target discovery, and validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide drug conjugates market also includes sales of peptide payload linkers, synthetic peptides, peptide targeting ligands, and drug delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.